1. Persistence of Human Papillomavirus, Overexpression of p53, and Outcomes of Patients After Endoscopic Ablation of Barrett's Esophagus 
Shanmugarajah Rajendra, Bin Wang, Darren Pavey, Prateek Sharma, Tao Yang, Cheok Soon Lee, Neil Gupta, Madeleine J. Ball, Raghubinder Singh Gill, Xiaojuan Wu 
Clinical Gastroenterology and Hepatology 
Volume 13, Issue 7, Pages e5 (July 2015)
DOI: /j.cgh
Copyright © 2015 AGA Institute Terms and Conditions

2. Figure 1
HR-HPV/P53 (IHC) status and treatment outcome after endoscopic ablative therapy in BD/EAC patients. No BD/EAC recurrence was detected during the course of the study. LGD, low-grade dysplasia.
Clinical Gastroenterology and Hepatology  , e5DOI: ( /j.cgh )
Copyright © 2015 AGA Institute Terms and Conditions

3. Figure 2
ISH detection of transcriptional activity of hr-HPV 16 and 18 E6/E7 mRNA in (A) HPV16+ cervical squamous cell carcinoma, (B) HPV16+ head and neck squamous cell carcinoma; (C) HPV-16/18 positive EAC, and (D) Barrett’s esophagus with HGD. Positive staining is diffusely present in the nuclei and cytoplasm as punctate/granular appearance. (E) HPV DNA negative samples of EAC and (F) Barrett’s HGD. No signals were detected in (E) and (F).
Clinical Gastroenterology and Hepatology  , e5DOI: ( /j.cgh )
Copyright © 2015 AGA Institute Terms and Conditions

4. Supplementary Figure 1
Rate of clearance of disease and abnormal laboratory results after RFA in patients with different pretreatment laboratory results. Hazard ratios estimated by using Cox proportional hazards regression, adjusted for number of RFA treatments (log transformed) (hazard ratio, 0.53; 95% CI, 0.35–0.82; P = .002), body mass index (hazard ratio, 0.68; 95% CI, 0.31–1.47; P = .41), and male gender (hazard ratio, 1.48; 95% CI, 1.05–1.77; P = .019) with body mass index a time-variable covariate (hazard ratio, 1.36; 95% CI, 1.08–1.46; P = .002), with each covariate being a standardized normal transformation of the raw covariate ([value-mean]/standard deviation); P values corrected for multiple comparisons by using the Holm method. Note that hazard ratio greater than 1.00 indicates faster clearance of disease, whereas hazard ratio less than 1.00 indicates slower clearance of disease. Two patients in the p53 IHC positive group were excluded from this analysis because no biopsies were available before 24 months and 33 months after first ablation. The time-to-event analysis indicates that clearance of disease was slower in HGD and EAC compared with LGD. Clearance of disease was slower when transcriptionally active HPV was present and also when p53 IHC was positive compared with patients without these abnormal laboratory results at the pre-ablation biopsies. When either biologically active HPV or p53 overexpression was initially present, the rate of clearance of the abnormal histologic results and laboratory results appeared to be similar (hazard ratio, 1.10; 95% CI, 0.71–1.71; P = .67; n = 26).
Clinical Gastroenterology and Hepatology  , e5DOI: ( /j.cgh )
Copyright © 2015 AGA Institute Terms and Conditions